Table 3.xls (5.5 kB)
Predicted coverage based on in vitro neutralizing activity of VRC01.
dataset
posted on 2017-11-14, 18:25 authored by Kenneth H. Mayer, Kelly E. Seaton, Yunda Huang, Nicole Grunenberg, Abby Isaacs, Mary Allen, Julie E. Ledgerwood, Ian Frank, Magdalena E. Sobieszczyk, Lindsey R. Baden, Benigno Rodriguez, Hong Van Tieu, Georgia D. Tomaras, Aaron Deal, Derrick Goodman, Robert T. Bailer, Guido Ferrari, Ryan Jensen, John Hural, Barney S. Graham, John R. Mascola, Lawrence Corey, David C. MontefioriPredicted coverage based on in vitro neutralizing activity of VRC01.
History
Usage metrics
Categories
Keywords
dosepeak serum VRC 01 levelsHVTNfindings HIV Vaccine Trials Network249 IV infusionstreatment group 1treatment group 3Serum VRC 01 levels208 SC injectionsTrial registration Clinical Trials RegistrationmgConclusions VRC 01CD 4 binding siteVRC 01 concentrationsanti-VRC 01 antibodies8 weeksCI2 weeksVRC 01 administration regimen6 United StatesSHIVtreatment group 2simian-human immunodeficiency virusplacebo group 3ICIV infusion seriesVRC 01phase 1 randomized trial Background VRC 01NCTVRC 01 administration
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC